| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
Harmalol targets multiple biological pathways. It is an inhibitor of monoamine oxidase (MAO), particularly MAO-A, which is involved in the metabolism of neurotransmitters. Harmalol also has antioxidant properties and may protect cells from oxidative stress. The compound may interact with various receptors and enzymes, contributing to its diverse pharmacological effects. However, its primary molecular target is not definitively established.
|
|---|---|
| ln Vitro |
Harmalol exhibits MAO inhibitory activity, antioxidant effects, and potential neuroprotective properties in vitro. It has been shown to protect neurons from oxidative stress-induced damage. The compound may also have anti-inflammatory effects. However, specific IC50 values and detailed in vitro activity data are limited compared to better-studied harmala alkaloids.
|
| ln Vivo |
In vivo, harmalol has been studied for its potential neuroprotective and antioxidant effects in animal models. It may protect against oxidative stress-related damage. The compound's MAO inhibitory activity may contribute to its effects on neurotransmitter metabolism. However, detailed in vivo efficacy data are limited. Harmalol is a naturally occurring alkaloid and a metabolite of harmaline.
|
| Enzyme Assay |
MAO inhibition assays are performed using recombinant MAO-A or MAO-B enzymes and appropriate substrates. The enzyme is incubated with substrate and varying concentrations of harmalol. The reaction product is measured by fluorescence or spectrophotometry. IC50 values are calculated from concentration-response curves. Antioxidant activity is assessed using DPPH, ABTS, or FRAP assays.
|
| Cell Assay |
Cellular assays for harmalol employ neuronal cell lines or other relevant cell types. Cells are treated with varying concentrations of harmalol for 24-72 hours. Cell viability is assessed using MTT or CellTiter-Glo assays. ROS levels are measured using fluorescent probes such as DCFH-DA. Neuroprotective effects are assessed by treating cells with oxidative stress-inducing agents in the presence or absence of harmalol.
|
| Animal Protocol |
In vivo studies with harmalol are typically performed in rodent models of neurological disorders. The compound is administered via oral or intraperitoneal routes at various doses. Neuroprotective effects are assessed in models of oxidative stress or neurodegeneration. Tissue samples are collected for biochemical analysis. However, detailed published in vivo protocols for harmalol are limited.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Halmolol is a known metabolite of halamine in the human body. Harmalol has molecular formula C12H12N2O and molecular weight 200.24. It has CAS number 525-57-5. The compound is a naturally occurring beta-carboline alkaloid found in plants including Peganum harmala. It is a metabolite of harmaline and is structurally related to harmine and harmol. It is soluble in DMSO and other organic solvents. The compound should be stored at -20°C for long-term stability. |
| Toxicity/Toxicokinetics |
Toxicological data for harmalol are limited. As a naturally occurring alkaloid, it may have psychoactive effects at high doses. The compound should be handled with appropriate laboratory safety precautions. Standard toxicological studies would be required for any therapeutic development. Harmalol is structurally related to other harmala alkaloids with known pharmacological effects.
|
| Additional Infomation |
Harmalol is a halman alkaloid in which the halman skeleton is substituted with a hydroxyl group at the C-7 position and the 3,4 bond is reduced. It is an EC 1.4.3.4 (monoamine oxidase) inhibitor and an algal metabolite. It is derived from the hydride of halman. Harmalol has been reported to exist in Polygala tenuifolia, Passiflora amethystica, and other organisms with relevant data.
Harmalol is a naturally occurring beta-carboline alkaloid found in Peganum harmala and is a metabolite of harmaline. It belongs to the harmala alkaloid family and is structurally related to harmine and harmol. Harmalol has been studied for its MAO inhibitory activity, antioxidant effects, and potential neuroprotective properties. It is a research-use only compound. |
| Molecular Formula |
C12H12N2O
|
|---|---|
| Molecular Weight |
200.23648
|
| Exact Mass |
200.095
|
| CAS # |
525-57-5
|
| Related CAS # |
6028-07-5 (hydrochloride)
|
| PubChem CID |
3565
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.28g/cm3
|
| Boiling Point |
507.5ºC at 760mmHg
|
| Melting Point |
211-212ºC
|
| Flash Point |
231ºC
|
| Index of Refraction |
1.708
|
| LogP |
1.674
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
15
|
| Complexity |
289
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=NCCC2=C1NC3=C2C=CC(=C3)O
|
| InChi Key |
RHVPEFQDYMMNSY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H12N2O/c1-7-12-10(4-5-13-7)9-3-2-8(15)6-11(9)14-12/h2-3,6,14-15H,4-5H2,1H3
|
| Chemical Name |
1-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-7-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9940 mL | 24.9700 mL | 49.9401 mL | |
| 5 mM | 0.9988 mL | 4.9940 mL | 9.9880 mL | |
| 10 mM | 0.4994 mL | 2.4970 mL | 4.9940 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
